9月14日，葛兰素史克盘中上涨4.07%，报50.0美元/股，成交额2419.23万美元。
消息面上，公司公布旗下肺癌药物zidesamtinib（商品名Jideytro）一线治疗临床试验数据，在未经靶向治疗的晚期ROS1阳性肺癌患者中实现94%的客观缓解率；脑转移患者应答率达100%，其中70%实现完全肿瘤清除。安全性方面，仅11%患者需减量、1%停药。公司计划年内向FDA提交一线适应症扩展申请。此外，GSK授权方翰森制药报告其ADC药物Ris-Rez治疗复发性小细胞肺癌的III期试验达到主要终点，进一步提振市场对GSK肿瘤管线的信心。当日医疗保健板块整体走强，行业ETF盘前涨约1.2%，阿斯利康、强生等同业亦录得涨幅。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.